Fusion is a clinical-stage biopharmaceutical company pioneering next-generation radiopharmaceuticals for cancer treatment. Our Targeted Alpha Therapies (TAT) platform and proprietary Fast-Clear™ linker technology enable precise, safer tumor targeting. We aim to revolutionize radiotherapeutics, improving patient outcomes across multiple tumor types.
Our website uses cookies to ensure you get the best experience. Learn more about the policy.